Skip to main content
. Author manuscript; available in PMC: 2016 Feb 9.
Published in final edited form as: Am J Cardiol. 2015 Sep 10;116(11):1752–1755. doi: 10.1016/j.amjcard.2015.08.042

Figure 1.

Figure 1

Selection of patients with cancer for retrospective assessment of bilirubin and anthracycline-induced LV systolic dysfunction. Data from 751 participants were analyzed after excluding 654 patients with cancer because they did not have a post-anthracycline LV systolic function assessment and 51 patients with cancer for total bilirubin >2 mg/dl.